FDA clears Tykerb for breast cancer

Categories: Breast Cancer

U.S. health regulators have approved GlaxoSmithKline Plc’s oral medication Tykerb for patients with advanced breast cancer after other treatments have failed, a company spokeswoman said on Tuesday.

Tykerb (lapatinib) is a tyrosine kinase inhibitor of HER2 and epidermal growth factor receptor. It blocks the intracellular HER-2/neu protein, whereas Herceptin (trastuzumab) blocks HER-2/neu on the outside of cancer cells.

The drug was approved for once-daily use in combination with Roche’s oral chemotherapy drug Xeloda, or capecitabine, Glaxo spokeswoman Mary Anne Rhyne said.

You Might Like:
  • High-dose chemo doesn’t improve survival in metastatic breast cancer
  • Comorbidity reduces benefits of androgen suppression in prostate cancer
  • Statins don’t appear to be linked with breast cancer risk
  • Soft-tissue sarcoma outcomes vary widely by race, ethnicity
  • Even small copay deters mammogram use: U.S. study
  • Effective prostate cancer screening requires digital rectal exam
  • Clinical trial access more limited for teen cancer patients
  • MicroRNA signatures linked with AML prognosis, cytogenetics
  • Stop-and-go oxaliplatin effective in elderly colon cancer patients
  • In vitro fertilization safe in women treated for endometrial carcinoma
  • High-dose methotrexate effective treatment for primary CNS lymphoma
  • Docetaxel every three weeks best for certain metastatic prostate cancers
  • Chewing gum after cystectomy stimulates return of bowel motility
  • Surgeon factors affect receipt of radiotherapy for breast cancer
  • Multimodal treatment may help in invasive bladder cancer
    •

    Leave a Reply

    « Green tea plus painkiller slows prostate cancer
    Corpse, cancer images to confront Indian smokers »